In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Care Reform and Business Development: 10 Reasons It Matters

Executive Summary

The drama of the US health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.

Related Content

Health Care Reform: For Biopharmas There Is Much To Like
Building A Biopharma Product's Reimbursement Into Deals
Biopharma Trends: Nowhere To Go But Up
Abbott Buys Solvay Pharma Unit But Is It Just A Short-Term Fix?
Limiting Cost-sharing on Drugs: A Big PhRMA Objective from Health Reform
Dollars for Donuts: Inside the Key Elements of PhRMA's Health Reform Deal
Tight Credit Renews Interest In Lowering Tax On Repatriated Income
Pfizer/Wyeth: Industrializing Pharma?
Pfizer/Wyeth: Industrializing Pharma?
Mind Your Bs and Ds


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts